A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum
tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation
schedule in subjects with relapsed or refractory B-cell CLL.